Skip to main content

Market Overview

Anavex Life Sciences Jumps 28% After Promising Results From Parkinson's Trial


Shares of micro cap biopharmaceutical company Anavex Life Sciences Corp. (NASDAQ: AVXL) traded up more than 28 percent on Thursday, following the announcement of promising preclinical data (from a Phase 2a clinical trial) for ANAVEX 2-73 in Parkinson's disease.

The product candidate a sigma-1 receptor agonist, showed success in restoring function in a classic animal model of Parkinson’s disease, causing considerable improvements on all three endpoints: behavioral, histopathological, and neuroinflammatory.

Related Link: Cynapsus Therapeutics Developing New Parkinson's Treatment That Won't Require Injection

“This initial data is encouraging, and together with already available clinical safety and tolerability data on ANAVEX 2-73, might accelerate the exploration of ANAVEX 2-73 as a potential therapeutic intervention in Parkinson’s disease,” President and CEO Christopher U. Missling, PhD explained.

The main authors of the study, Veronica Francardo, PhD, and Angela Cenci, PhD, added, “We are in the fortunate situation that safety and tolerability of this compound have already been proven in human subjects, and that preliminary indications of a cognitive benefit have been obtained in a Phase 2a clinical trial for Alzheimer’s disease.”

Shares traded recently at $3.31.


Related Articles (AVXL)

View Comments and Join the Discussion!

Posted-In: Parkinson's Parkinson's DiseaseBiotech News Health Care Movers General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at